News

September 14, 2018

Interview with Greg Mayes of Engage Therapeutics

Greg Mayes is the president, CEO, and founder of Engage Therapeutics, founded in 2017 to clinically develop and progress a product called staccato alprazolam, which had […]
September 14, 2018

What The After Party Gets Right About Epilepsy

“When an aspiring rapper goes viral for all the wrong reasons, he thinks his career is over. But when his best friend gets them into a […]
August 13, 2018

A FACES-Inspired Clinical Trial – Engage Therapeutics CEO, Greg Mayes

Read the article by Greg Mayes, Engage Therapeutics CEO, in FACES Annual Newsletter 2018: View the full newsletter here (PDF)
June 27, 2018

Engage Therapeutics CEO, Greg Mayes, makes opening remarks to Clinical Investigators at the StATES Investigator Meeting. New Orleans, LA – June 8, 2018

Engage Therapeutics CEO, Greg Mayes, makes opening remarks to Clinical Investigators at the StATES Investigator Meeting. New Orleans, LA – June 8, 2018
May 18, 2018

STACCATO® ALPRAZOLAM

G. Mayes CEO, Engage Therapeutics, Summit, NJ, United States Staccato Alprazolam (STAP-001) is a single-use, hand-held, drug-device combination product that provides rapid systemic delivery by inhalation […]
April 30, 2018

Engage Therapeutics Doses First Patient in Phase 2b Trial of Epilepsy Seizure Rescue Therapy Staccato® Alprazolam

Peachtree BioResearch Solutions to Execute Multi-Center Trial SUMMIT, N.J. – April XX, 2018 – Engage Therapeutics, Inc., today announced dosing of the first patient in its […]
April 20, 2018

Engage Therapeutics Announces $23 Million Series A Financing to Advance Phase 2b Development of Novel Epileptic Seizure Rescue Therapy

SUMMIT, N.J., Sep. 27, 2017 – Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced […]